ft 02 apr 93 lex column right medicin pharmaceut sector well use right issu medeva made convent mould yesterday pound 94m cash call enabl buy anoth hand readi made product market small interest industri giant odd tradit drug compani found squar medic research regul competit squeez organ growth across sector though one might reason wonder whether other forc adapt thought glaxo might fund move counter medicin right issu credibl enough give market shake medeva unusu approach made immun malais afflict rest sector sinc compani fund ambit paper inconveni price earn ratio far market averag hardli buy posit strength price latest buy suggest bargain still found among smaller privat own drug compani whether medeva find enough opportun maintain growth rate without buy dud get unwis area remain open question sensit rate might explain medeva strenuou effort make transpar earli adopt frs3 help interpret previous opaqu record earn growth organ growth evid recent full year figur encourag other might end follow medeva path acquisit never univers cure